Herpes Market to 2018 - Genericization Compels Competitors Seeking Differentiation

April 5, 2012 - PRLog -- Demand is rising for new and improved treatments for herpes to prevent the virus becoming deadly in immunosuppressed patients, such as those undergoing organ transplantation, or those with AIDS, according to a new report by business intelligence experts GBI Research.

The new report* states that more can be done for immune-compromised individuals facing life-threatening battles against the herpes virus, which causes relatively minor symptoms in the normal population. As medicine has advanced, more people survive in immune-compromised states, but subsequently form a population which desperately needs medical protection against common viruses.

The current herpes treatment market can only offer symptomatic treatment for herpes simplex and herpes zoster infections, as no curative therapies exist, and infections can recur after a course of treatment. The market has limited scope for growth, due to the presence of generic products at low prices, and a lack of innovation in upcoming pipeline products. However, the market holds a high level of demand for new therapeutics that can provide curative treatments, non-toxic congenital herpes treatments, and Cytomegalovirus (CMV) treatments.

CMV infections are generally undetected in healthy individuals, but can become dangerous in immunosuppressed individuals, whose natural defenses are lowered due to AIDS/HIV infection, stem cell or organ transplants, and any other condition which is treated with immunosuppressant drugs, such as multiple sclerosis or Crohn’s disease. Advancing surgical abilities and a rising treatment rate of HIV has led to a steadily growing population under significant threat from CMV infections, and this in turn is increasing the financial rewards for a company who can produce a future blockbuster treatment.

For Sample Pages, please click or add the below link to your browser:
http://www.gbiresearch.com/RequestSamplePages.aspx?ID=Her...


Promising therapies are expected to be launched for CMV infections in the future. Nine molecules in Phase III of the clinical development pipeline are being developed to treat various herpes infections, and these include several first-in-class molecules. However, remaining unmet needs will spur the therapeutics market on to discover curative therapeutics, and new antiviral therapies which the virus has not yet built any resistance against.

The value of the global herpes market is estimated to have been approximately $4.2 billion in 2010, and is projected to grow at a CAGR of 10.1% until reaching $9.1 billion by 2018.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.

For further details, please click or add the below link to your browser:
http://www.gbiresearch.com/Report.aspx?ID=Herpes-Market-t...

Visit our report store: http://www.gbiresearch.com
For more details contact:
pressreleases@gbiresearch.com            
North America:                   +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GBI Research is a market-leading provider of business intelligence reports. GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders’ insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.